Concentrations of Alpha-Fetoprotein,Insulin-Like Growth Factor Binding Protein-3,c-erbB-2,and Epidermal Growth Factor in Serum of Patients With Endometriosis
Restricted accessResearch articleFirst published online April, 2004
Concentrations of Alpha-Fetoprotein,Insulin-Like Growth Factor Binding Protein-3,c-erbB-2,and Epidermal Growth Factor in Serum of Patients With Endometriosis
Objective:Endometriosis, although it is a benign disorder, shares many similarities with cancer. There is incresing levels of evidence suggesting that some circulating factors involved in gynecologic cancers, such as alpha-fetoprotein (AFP), insulin-like growth factor binding protein-3 (IGFBP-3), c-erbB-2) (HER-2/neu), and epidermal growth factor (EGF), could also play a role in endometriosis. Hence, the present study was aimed at evaluating whether the levels of these molecules are modulated in the serum of patients with endometriosis.
Methods:Levels of AFP, IGFBP-3, c-erbB-2, and EGF were determined by enzyme-linked immunosorbent assay in serum from 36 subjects with surgically confirmed endometriosis and 36 controls with no surgical evidence of the disease. In addition, information such as demographic characteristics, personal habits, menstrual characteristics, and clinical profile was collected from each participating subject.
Results:No significant difference was found between serum levels of AFP, IGFBP-3, c-erbB-2, and EGF in patients with endometriosis and controls, even when we adjusted for potential confounders and took into account the menstrual cycle. Moreover, no correlation was observed between the serum concentrations of these molecules and the stage of the disease. However, a correlation was detected between soluble levels of IGFBP-3 and presence of uterine leiomyoma.
Conclusion:Although AFP, IGFBP-3, c-erbB-2, and EGF are not altered in the circulation of patients with endometriosis, their involvement in the development of endometriotic lesions cannot be excluded.
1. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am1997;24:235-258.
2.
2. Sampson JA. Periotoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol1927;14:422-469.
3.
3. Gosselin D, Shazand K, Miron P, Lavoie HB, Domin M, Hugo P. Insights into the physiopathology of endometriosis—novel diagnostic and therapeutic approaches. Curr Opin Oncol Endo Metab Invest Drugs1999;1:31-43.
4.
4. Swiersz LM. Role of endometrosis in cancer and tumor development. Ann N Y Acad Sci2002;955:281-292.
5.
5. Sarcione EJ, Biddle W. Elevated serum alpha fetoprotein levels in postmenopausal women with primary breast carcinoma. Dis Markers1987;5:75-79.
6.
6. Motawy MS, Szymendera JJ, al-Jazzaf H, et al. Serum AFP, hCG and CEA in the management of patients with testicular, ovarian and extragonadal germ cell tumors. Int J Biol Markers1992;7:80-86.
7.
7. Sell A, Sogaard H, Norgaard-Pedersen B. Serum alpha-fetoprotein as a marker for the effect of post-operative radiation therapy and/or chemotherapy in eight cases of ovarian endodermal sinus tumour. Int J Cancer1976;18:574-580.
8.
8. Koyama Y, Taketa K, Azuma M, Yamamoto R, Fujimoto S,Nishi S. Biochemical characterization of alpha-fetoprotein and other serum proteins produced by a uterine endometrial adenocarcinoma. Jpn J Cancer Res1996;87:612-617.
9.
9. Joseph MG, Fellows FG, Hearn SA. Primary endodermal sinus tumor of the endometrium. A clinicopathologic, immunocytochemical, and ultrastructural study. Cancer1990;65:297-302.
10.
10. Ohta M, Sakakibara K, Mizuno K, et al. Successful treatment of primary endodermal sinus tumor of the endometrium. Gynecol Oncol1988;31:357-364.
11.
11. Matsukuma K, Tsukamoto N. Alpha-fetoprotein producing endometrial adenocarcinoma: Report of a case. Gynecol Oncol1988;29:370-377.
12.
12. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst2000;92:1472-1489.
13.
13. Koutsilieris M, Akorum A, Lazure C, Frenette G, Lemay AN-terminal truncated forms of insulin-like growth factor binding protein-3 in the peritoneal fluid of women without laparoscopic evidence of endometriosis. Fertil Steril1995;63:314-321.
14.
14. Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: Update 2002. Maturitas2002;41Suppl 1:S65-S83.
15.
15. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res2003;284-99-110.
16.
16. Ebert AD, Wechselberger C, Martinez-Lacaci I, Bianco C, Weitzel HK, Salomon DS. Expression and function of EGF-releated peptides and their receptors in gynecological cancer—from basic science to therapy. J Recept Signal Transduct Res2000;20:1-46.
17.
17. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig1996;3:99-105.
18.
18. Brandt-Rauf PW. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res1995;333:203-208.
19.
19. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. Eur J Obstet Gynecol Reprod Biol1997;71:173-179.
20.
20. Pittaway DE. Serum markers of endometrium and endometriosis. In: Diamond MP, Osteen KG, eds. Endometrium and endometriosis. Malden: Blackwell Science, 1997:31-41.
21.
21. Gagné D, Rivard M, Pagé M, Shazand K, Hugo P, Gosselin D. Blood leukocyte substs are modulated in patients with endometriosis. Fertil Steril2003;80:43-53.
22.
22. American Society for Reproductive Medicine (ASRM). Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril1997;67:817-821.
23.
23. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol1975;122:262-263.
24.
24. Zhou J, Dsupin BA, Giudice LC, Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab1994;79:1723-1734.
25.
25. Moller B, Rasmussen C, Lindblom B, Olovsson M, Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod2001;7:65-72.
26.
26. Imai T, Kurachi H, Adachi K, et al. Changes in epidermal growth factor receptor and the levels of its ligands during menstrual cycle in human endometrium. Biol Reprod1995;52:928-938.
27.
27. Akinbiyi AA. Unexplained elevated maternal serum alpha-feto-protein in singleton pregnancies as a predictor of fetal risk. Int J Gynaecol Obstet1996;53:17-21.
28.
28. Moore MP, Redman CW. Case-control study of severe preeclampsia of early onset. Br Med J (Clin Res Ed)1983;287:580-583.
29.
29. Vollenhoven BJ, Herington AC, Healy DL. Messenger ribonucleic acid expression to the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab1993;76:1106-1110.
30.
30. Wang DP, Konishi I, Koshiyama M, et al. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows Arch A Pathol Anat Histophatol1992;421:393-400.
31.
31. Inaji H, Koyama H, Motomura K, et al. Simultaneous assay of erbB-2 protein and carcinoembryonic antigen in cyst fluid as an aid in diagnosing cystic lesions of the breast. Breast Cancer1994;1:25-30.
32.
32. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reception. J Clin Endocrinol Metab1994;78:1179-1184.
33.
33. Yeh J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril1991;56:997-1000.
34.
34. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H. Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab2000;85:3292-3296.
35.
35. Osteen KG, Bruner-Tran KL, Keller NR, Eisenberg E. Progesterone-mediated endometrial maturation limits matrix metalloproteinase (MMP) expression in an inflammatory-like environment: A regulatory system altered in endometriosis. Ann N Y Acad Sci2002;955:37-47.
36.
36. Gagné D, Pagé M, Robitaille G, Hugo P, Gosselin D. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod2003;18:1674-1680.
37.
37. Steff AM, Gagné D, Pagé M, Rioux A, Hugo P, Gosselin D. Serum concentrations of insulin-like growth factor-1, soluble tumor necrosis factor receptor-1 and angiogenin in endometriosis patients. Am J Reprod Immunol2004;51:166-173.
38.
38. Hoppener JW, Mosselman S, Roholl PJ, et al. Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J1988;7:1379-1385.
39.
39. Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan. J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev1990;27:93-101.
40.
40. Strawn EY Jr, Novy MJ, Burry KA, Bethea CL. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol1995;172:1837-1843.
41.
41. Abrao MS, Podgaec S, Pinotti JA, de Oliveira RM. Tumor markers in endometriosis. Int J Gynaecol Obstet1999;66:19-22.
42.
42. Akoum A, Lemay A, Lajeunesse Y, Marois M, Koutsilieris M. Immunohistochemical localization of insulin-like growth factor-binding protein-3 in eutopic and ectopic endometrial tissues. Fertil Steril1999;72:1085-1092.
43.
43. Taskin O, Giudice L, Mangal R, et al. Insulin-like growth factor binding proteins in peritoneal fluid of women with minimal and mild endometriosis. Hum Reprod1996;11:1741-1746.
44.
44. Kim JG, Suh CS, Kim SH, Choi YM, Moon SY, Lee JY. Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the periotoneal fluid of patients with and without endometriosis. Fertil Steril2000;73:996-1000.
45.
45. Gurgan T, Bukulmez O, Yarali H, Tanir M, Akyildiz S. Serum and perioneal fluid levels of IGF I and II and insulinlike growth binding protein-3 in endometriosis. J Reprod Med1999;44:450-454.
46.
46. Bergqvist A, Borg A, Ljungberg O. Protooncogenes in endometriotic and endometrial tissue. Ann N Y Acad Sci1991;626:276-283.
47.
47. Hammond MG, Oh ST, Anners J, Surrey ES, Halme J. The effect of growth factors on the proliferation of human endometrial stromal cells in culture. Am J Obstet Gynecol1993;168:1131-1136.
48.
48. Taketani Y, Mizuno M. Hormonal regulation of endometriotic cell growth in primary cell culture system. Arch Gynecol Obstet1992;251:127-132.
49.
49. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci2002;955:89-100.
50.
50. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril1993;59:681-684.
